Purpose Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I study was designed to explore the combination of topotecan with the MET TKI tivantinib. Methods Eligible patients with advanced solid malignancies for which there was no known effective treatment received topotecan at doses of 1.0-1.5 mg/m 2 /day for five consecutive days in 21-day cycles with continuous, oral tivantinib given at escalating doses of 120-360 mg orally twice daily. Pharmacokinetic analyses of tivantinib were included. Circulating tumor cells (CTC) were collected serially to identify peripheral changes in MET phosphorylation. Results The trial included 18 patients, 17 of whom received treatment. At the planned doses, the combination of topotecan and tivantinib was not tolerable due to thrombocytopenia and neutropenia. The addition of G-CSF to attenuate neutropenia did not improve tolerability. Greater tivantinib exposure, assessed through pharmacokinetic analysis, was associated with greater toxicity. No responses were seen. MET phosphorylation was feasible in CTC, but no changes were seen with therapy. Conclusions The combination of topotecan and oral tivantinib was not tolerable in this patient population.
Introduction
Dysregulation of the MET signaling cascade is implicated in numerous types of cancer, in part due to its role in essential biologic processes such as cell survival, proliferation and migration [1, 2] . With downstream effectors in the mitogen activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and nuclear factor-KB pathways (NF-KB), MET plays a central role in many transformed cells and consequently, remains an appealing therapeutic target [3, 4] . There are several MET inhibitors in development, including tivantinib (ARQ-197), a potent, orally bioavailable MET tyrosine kinase inhibitors (TKI).
While monotherapy with a MET TKI has shown promise in various cancer subtypes, including non-small cell lung cancer [5] , combination strategies have been explored to increase the therapeutic index. Inhibition of MET and topoisomerase I, the target of the cytotoxic agent topotecan, resulted in a synergistic decrease in cell viability in preclinical small cell lung cancer (SCLC) models [6] . To explore this potential synergy, we designed a phase I trial of intravenous (IV) topotecan plus tivantinib.
Materials and methods

Patients and design
This phase I trial (NCT01654965) was conducted under the U01 co-operative agreement between the California Cancer Consortium (CCC) and the National Cancer Institute (NCI). The study was conducted at seven centers in the United States and was approved by the institutional review boards at each institution. The primary objective of this study was to establish the recommended phase 2 dose (RP2D) for the combination of tivantinib and IV topotecan. Secondary objectives were to describe the toxicities of the combination, to characterize the pharmacokinetic behavior of tivantinib with concurrent IV topotecan, and explore the efficacy of this combination. The study included a dose-escalation portion and an expansion portion in patients with SCLC.
Eligible patients in the dose escalation portion had advanced solid malignancies refractory to or relapsed from standard therapies, or for which there was no known effective treatment. Eligible patients in the expansion portion had SCLC previously treated with platinum-based chemotherapy. Other inclusion criteria included ECOG performance status 0-2, adequate organ and marrow function, and ability to take oral medications. Patients with creatinine levels above the institutional normal range were required to have a calculated creatinine clearance of at least 60 ml/min. Patients who had received chemotherapy or radiotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C) were excluded. Also excluded were patients with untreated brain metastases, active infection or other uncontrolled intercurrent illness.
This study was conducted in accordance with principles of the Declaration of Helsinki and Good Clinical Practice guidelines and with local ethics committee approval and was registered (NCT01654965). Written informed consent was obtained from all patients.
Treatment
Treatment was administered on an outpatient basis. Topotecan was administered IV over 30 min on days 1-5 of a 21-day cycle with dexamethasone and an anti-emetic premedication. Tivantinib was given orally, twice daily, on a continuous schedule starting on day 1. The study explored combinations with tivantinib at doses between 120 and 360 mg orally twice daily with topotecan at doses of 1.0-1.5 mg/m 2 /day (Table 1) . Initially, up to four dose levels were planned: three escalation doses and one deescalation dose. The study was amended after completing the first two dose levels (levels 1 and − 1) to include two additional dose levels (A1 and A2) with mandatory use of granulocyte-colony stimulating factor (G-CSF) given subcutaneously at least 24 h after completion of topotecan. Treatment could continue until disease progression, unacceptable toxicity, delays in treatment for over 21 days, or the need for more than two dose reductions.
Study assessments
Toxicity was graded using the Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 4.0. Dose limiting toxicity (DLT) was at least possibly attributable to the regimen of tivantinib and topotecan and defined as: Grade 3 + thrombocytopenia, Grade 3 + neutropenia associated with fever or a clinically significant infection or lasting more than 7 days, or any clinically significant Grades 3 or 4 toxicity excluding Grades 3 or 4 nausea or vomiting despite maximal antiemetic therapy; Grades 3 or 4 diarrhea despite anti-diarrheal therapy; and Grade 3 fatigue. Any treatmentrelated toxicity resulting in a delay of treatment for over 21 days was also considered a DLT. Patients who during cycle 1 received less than 80% of the planned doses of either tivantinib or topotecan for reasons other than toxicity and did not experience a DLT were replaced for the purposes of evaluating the dose level for dose escalation/de-escalation decisions.
Patients underwent radiographic evaluation and tumor measurements at baseline and then after every two cycles. Confirmatory scans were required at 6 weeks following initial documentation of an objective response. Overall response was graded according to RECIST v1.1. Overall complete response (CR) and partial response (PR) were considered objective responses. Blood was collected for tivantinib pharmacokinetic (PK) analysis during the first cycle on day 1 prior to tivantinib or topotecan administration, on day 5 prior to tivantinib or topotecan administration (12 h after the evening tivantinib dose on day 4) and after topotecan and tivantinib administration (at 2, 3, 4, and 8 h). Tivantinib concentrations were measured using high-performance liquid chromatography (HPLC) and tivantinib steady-state plasma pharmacokinetics were calculated including C max (ng/ml), AUC 0-8 h (ng × h/ml), AUC 0-infinity (ng × h/ml), and Cl sys (l/h).
Pharmacodynamics
Blood for analysis of circulating tumor cells (CTCs) was collected pre-study, on day 2 of treatment, prior to cycle 3 of treatment and within 2 weeks of last treatment. At these specified time points, 7.5 ml of peripheral blood was drawn by standard venipuncture into two CellSave tubes. Tubes underwent Ficoll-Hypaque centrifugation to deplete red blood cells and to isolate the "buffy coat" layer containing CTCs and white blood cells (WBCs). The buffy coat was then passed through a slot microfilter using a constant low-pressure delivery apparatus. The microfilter-captured cells were fixed in 10% formalin and subjected to immunofluorescent ( 
Statistical methods
Evaluation of the dose levels followed the standard 3 + 3 dose escalation rules [7] . Dose escalation considerations were based on course 1 data only. The maximum tolerated dose (MTD) was to be the highest dose level tested at which 0/6 or 1/6 patients experienced DLT (that was possibly, probably, or definitely related to one or both of the study drugs) with at least 2/3 or 2/6 patients encountering DLT at the next higher dose. The RP2D would not exceed the MTD but may be below the MTD, based on additional considerations such as cumulative toxicities.
To examine the association between the PK parameters and hematologic toxicity, neutropenia was grouped as Grades 0-3 vs. Grade 4, and thrombocytopenia was grouped as Grades 0-1 vs. Grades 2-4-in both cases, taking the maximum grade over all courses. Plots and exact logistic regression were used to describe the patterns; the Wilcoxon Rank Sum test was used to compare PK values between patients with or without Grade 3 + thrombocytopenia or Grade 4 neutropenia.
Results
Patient characteristics
Eighteen patients were enrolled from August 2012 through September 2014. No patients were determined to be ineligible after enrollment, but one patient never began treatment and is not included in this report. Characteristics of the 17 patients who were treated are provided in Table 2 . The median age was 63 years (range 26-77). The ECOG performance status for all patients was between zero (5 patients) and one (12 patients). There were six patients with primary lung cancer (3 with non-small cell lung cancer and 3 with SCLC), three with ovarian cancer, two with pancreatic cancer, and one patient with each of the following: liver, soft tissue, cervical, uterine, prostate, and urothelial.
Dose escalation and toxicity
A summary of the dose escalation is provided in Table 3 . At dose level 1, the first patient experienced two DLTs in the first cycle: Grade 3 thrombocytopenia and grade 4 neutropenia persisting for more than 7 days. The patient recovered and received cycle 2. The second patient also had two DLTs in the first cycle: Grade 4 thrombocytopenia and a neutropenic fever. This patient's therapy was delayed for more than 21 days due to disease progression. The third patient at dose level 1 did not have a DLT, although there was a dose reduction due to Grade 3 neutropenia that did not last more than 7 days; the patient then received cycle 2. Based on two DLTs, the dose was de-escalated to level − 1 (Table 1) . At dose level − 1, the first patient experienced had a DLT: Grades 3-4 neutropenia lasting for more than 7 days. The next two patients were both properly dosed and did not have a DLT. After review of the first three patients, this dose level was expanded to enroll three more patients, but a decision was made to stagger entry by 2 weeks. The fourth patient was replaced since he did not receive 80% of both drugs. He experienced rectal hemorrhage attributed to hemorrhoids while receiving anticoagulation and discontinued therapy due to clinical decline. The next two patients were both properly dosed and did not have a DLT. A seventh patient also received less than 80% and therefore needed to be replaced. This patient experienced Grade 3 neutropenia and decreased WBC which did not persist for more than 7 days and therefore did not qualify as DLT. The eighth patient experienced a DLT in the first cycle: prolonged Grade 4 neutropenia and Grade 4 thrombocytopenia. His course was complicated by neutropenic sepsis and rhabdomyolysis. The patient died of acute renal failure and study accrual was suspended.
After discussion with the sponsor, G-CSF was added to attenuate the neutropenia and two additional doses (A1 and A2) were added (Table 1) . At dose level A1, the first patient experienced at DLT: Grade 3 thrombocytopenia. The next 2 patients were evaluable and did not experience DLT. Dose level A1 was expanded to enroll three more patients. The fourth and fifth patients did not experience a DLT, but neither had received sufficient drug to be evaluable for DLT assessment. The sixth patient experienced Grade 4 thrombocytopenia and the Grade 3 febrile neutropenia. With two DLTs at level A1, the dose exceeded the MTD. The combination was not felt to be tolerable and the study was permanently closed with no MTD determined. The expansion cohort was not opened.
Toxicities observed are summarized in Table 4 . With two exceptions at dose level A1 (fatigue and diarrhea), all Grade 3 or greater toxicities at least possibly attributed to treatment were hematologic. Decreasing the dose of tivantinib (from 240 to 120 mg twice daily) did not substantially decrease the frequency of Grade 3 or greater neutropenia or thrombocytopenia; nor did the use of G-CSF. As might be expected, patients who were able to continue treatment had fewer grade 3 or greater toxicities in subsequent cycles.
Pharmacokinetics
Twelve patients had adequate samples collected to allow calculation of tivantinib steady-state plasma pharmacokinetics. Table 5 summarizes the PK results. In the cohort of 11 patients treated at the MTD dose of 120 mg bid, the median steady state area under the curve (AUC) at 12 h was 12,031 ng h/ml (range 2697-50,290 ng h/ml), the median maximum plasma level was 1150 ng/ml (range 454-4550 ng/ml), and the median oral clearance was 10.0 l/h (range 2.4-44.5 l/h). A descriptive analysis was undertaken to examine the association between the PK values and the development of Grade 3 or greater thrombocytopenia or Grade 4 neutropenia. The patterns observed were as expected: higher toxicities were observed with greater tivantinib exposure. The associations were stronger for thrombocytopenia, but in this series, none of the associations were statistically significant at the 
Antitumor activity
No objective responses were seen. Seven of the 17 treated patients experienced a best response of stable disease. A median of 3 cycles were administered (range 1-12); 1 patient received 10 cycles and 2 patients received 12 cycles.
Fourteen (14) patients stopped protocol therapy due to progressive disease (PD) and 2 stopped due to clinical decline or early death.
Pharmacodynamics
Of the 14 patients with specimens collected for CTC analysis, 12 patients had detectable CTCs. There were no significant changes in pC-MET or p-FAK staining, though staining for these markers was found to be feasible on isolated CTCs (Fig. 3) .
Discussion
MET is an increasingly relevant therapeutic target in oncology, holding a central role in cancer progression and drug resistance [8] . Tivantinib is a potent, orally bioavailable inhibitor of C-MET that has been explored in numerous cancer subtypes. As a single agent, tivantinib is well tolerated and in the phase I dose escalation study, no maximum tolerated dose was identified [9] . Monotherapy with tivantinib has led to prolonged periods of disease control, but the response rate has been low. No responses were seen in single arm studies of patients with germ cell tumors [10] , gastric cancer [11] , and hepatocellular carcinoma [12, 13] and a response rate of only 5% was noted in patients with triple-negative breast cancer [14] .
Combining tivantinib with other active agents has been explored, including cytotoxic agents and targeted agents. These combinations have generally been well tolerated, including combinations of tivantinib plus gemcitabine [15] , irinotecan and cetuximab [16] , erlotinib [17] , sorafenib [18] , and temsirolimus [19] . Based on preclinical synergy between MET inhibition and topoisomerase I inhibition, a combination of tivantinib plus topotecan had potential relevance, particularly in diseases where topotecan played a clinical role. This phase I study explored the combination of tivantinib and topotecan with plans to pursue the combination in a cohort of patients with SCLC. Unfortunately, in contrast to prior combination studies, the combination of tivantinib and topotecan was not well tolerated. While the phase I dose escalation study of tivantinib did not identify a maximum tolerated dose, DLTs were noted including leucopenia, neutropenia and thrombocytopenia. The hematologic toxicity overlaps with the well described myelosuppression associated with topotecan [20] . Patients at higher risk for topotecan toxicity were excluded from this study, including those with poor creatinine clearance [21] or a poor performance status; however these patients were not included in this trial. Other at-risk populations could have been included, including those with a poor nutritional status [22] , which may have influenced the toxicity profile of this combination. The protocol was amended to include use of growth factors but even with this support, the combination was not tolerated and the study was terminated.
In preclinical studies, pharmacokinetics for tivantinib were evaluated and compared in mice, rats and dogs using different dosing routes, levels and formulations. In general, exposure to tivantinib increased as the dose was increased. The corresponding AUC 0-inf and C max were generally not dose proportional. After multiple dosing in 7-day, 28-day, 8-week, and 26-week studies, there were no consistent changes in C max and AUC values in rats or dogs, indicating that there was no marked accumulation of tivantinib after multiple dosings. The systemic exposures of tivantinib measured in patients enrolled on the current study were highly variable. As a result, the median steady-state AUC determined in our subjects receiving 120 mg bid was within the ranges of AUCs reported in patients taking 360 mg bid [9, 10, 23] . While we did not control for potential sources of pharmacokinetic variability such as CYP2C19 pharmacogenomic differences, potential drug-drug interactions, and possible food-effects on the oral absorption of tivantinib, it is unlikely that co-administration of topotecan contributed to the higher than expected tivantinib AUC since topotecan has not been shown to induce or inhibit cytochrome P450 enzymes (Hycamtin ® prescribing information). Pharmacokinetic studies were not performed for topotecan but tivantinib is not associated with renal impairment, which could impact topotecan clearance. Furthermore, tivantinib has not been shown to have a significant interaction with substrates of CYP1A, CYP2C9, CYP2C19, CYP3A4 or P-glycoprotein [24] .
Circulating tumor cells were isolated using a slot microfilter and detectable in 12 of 14 patients who provided specimens. Assaying pC-MET and p-FAK was feasible, though no meaningful conclusions can be made regarding changes in CTC number or phosphorylation of MET or FAK based on the small sample size.
It is worth noting that tivantinib may demonstrate activity independent of MET inhibition, as more recent studies suggest its primary mechanism is via tubulin depolymerization [25] . The strategy of combining a MET inhibitor with a topoisomerase inhibitor may still hold value, but avoiding overlapping hematologic toxicity will make for a better tolerated combination. While this combination was based on preclinical synergy and likely distinct pharmacokinetic pathways, the overlapping toxicity was too great for further development. Based on this phase I study, we do not recommend further study of the combination of tivantinib plus IV topotecan.
